Curated gurus reporting this holding
A curated subset of well-known investors — not the full institutional ownership.
- Greenlight Capital2,152,669주2026-06-30 · 증감 0주
- Viking Global Investors6,271,467주2026-06-30 · 증감 -380981주
Roivant Sciences company information
로이반트 사이언시스NASDAQ:ROIV · Nasdaq · Healthcare$35.72+0.62%
2026-10-02 closeRoivant Sciences's company information is shown as of 2026-10-02. It is a security listed on Nasdaq, ticker ROIV. There are 13 published related companies.
About this company
Roivant Sciences last closed at $35.72 (+0.62%) on 2026-10-02. Listed on Nasdaq.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F is quarterly and may be filed up to 45 days later.
Other stocks held by the same investors
A filing-based shared-holder record, not investment advice.
- Acadia Healthcare CompanyUSACHC-US →
Shared holders: Greenlight Capital
- Antero ResourcesUSAR-US →
Shared holders: Greenlight Capital
- Brighthouse FinancialUSBHF-US →
Shared holders: Greenlight Capital
- CignaUSCI-US →
Shared holders: Greenlight Capital
- Comcast Class AUSCMCSA-US →
Shared holders: Greenlight Capital
- CenteneUSCNC-US →
Shared holders: Greenlight Capital
- COYA THERAPEUTICSUSCOYA-US →
Shared holders: Greenlight Capital
- Capri HoldingsUSCPRI-US →
Shared holders: Greenlight Capital
Suppliers, competitors and related stocks
- PfizerCustomer
바토클리맙 등 공동개발·사업화 이력이 있는 주요 파트너
- SanofiCustomer
면역질환 신약 후보를 둘러싼 협력·라이선스 관계가 있는 대형 제약사
- NovartisCustomer
Roivant의 자산 라이선스·제휴 가능성이 있는 글로벌 제약사
- AbbVieCompetitor
면역·염증 및 희귀질환 파이프라인에서 경쟁하는 대형 제약사
- Bristol Myers SquibbCompetitor
면역학·종양학 신약개발에서 경쟁하는 글로벌 빅파마
- Eli LillyCompetitor
면역·대사·중추신경계 치료제 개발에서 경쟁하는 대형 제약사
- AmgenCompetitor
바이오의약품·희귀질환 영역에서 경쟁하는 주요 바이오텍/제약사
- Regeneron PharmaceuticalsCompetitor
항체 기반 치료제와 희귀질환 파이프라인에서 경쟁하는 바이오기업
- AstraZenecaCompetitor
면역질환·종양학 분야에서 경쟁하는 글로벌 제약사
- Takeda PharmaceuticalCompetitor
희귀질환·면역질환 중심 파이프라인에서 경쟁하는 글로벌 제약사
- ModernaRelated theme
바이오텍 플랫폼 기반 신약개발이라는 같은 투자 테마
- Blueprint MedicinesRelated theme
희귀질환·정밀의학 중심 바이오텍이라는 유사 테마
- PfizerRelated theme
대형 제약사와의 자산 라이선스/공동개발 모델이 Roivant의 핵심 테마
Major stocks in the same sector
2026-10-04 dataset
📦 ETFs holding this stock
by weight · top-10 constituents basisPassive money holding this stock ≈ $219M(lower bound — top-10 basis, not a forecast)
- Invesco DWA Healthcare Momentum ETF4.82%
- Adaptiv Select ETF4.49%
- Invesco S and P MidCap Momentum ETF2.55%
- Invesco FTSE RAFI US 1500 Small Mid ETF0.41%
Factual holdings info from daily disclosures — not a recommendation.
Look up another stock →Quantus Signal · live data · not investment advice · Privacy Policy